This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): AC165198
Description: AC165198, a peptide hybrid, is a fusion of two different peptide hormones.
Amylin and Biocon
In September 2009, Amylin Pharmaceuticals and Biocon announced that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs.
Under the terms of the Development and Commercialization Agreement, Amylin will provide expertise in peptide hormone development, particularly in the area of phybrid technology, as well as metabolic disease therapeutics. Biocon will utilize its expertise in recombinant microbial expression to manufacture the compound and also leverage its experience in preclinical and clinical development of diabetes products.
In January 2013, Biocon reported that they have terminated the agreement for the AC165198 partnered program with Amylin targeting diabetes and obesity.
Amylin and Bristol-Myers...See full deal structure in Biomedtracker
Partners: AstraZeneca PLC
Additional information available to subscribers only: